VSTM

VSTM

Verastem develops pharmaceutical treatments for cancer, operating in the pharmaceutical preparations industry.
The company is focused on creating targeted therapies for aggressive cancers, with a core strategy centered on developing kinase inhibitors to combat tumor resistance pathways.

$7.11 -0.68 (-8.73%)

Updated: January 12, 2026, 16:00 EST

Analyzed by Rockflow Bobby Quantitative Model āœ“ Updated Daily

Investment Opinion: Should I buy VSTM Today?

Analysis of VSTM

Technical Perspective VSTM shows significant technical weakness, with substantial declines over recent months and notable underperformance compared to the broader market. While the stock trades midway within its 52-week range, indicating no extreme conditions, the sharp maximum drawdown of over 51% highlights persistent downside pressure. The low beta suggests defensive traits, but this hasn't prevented severe price erosion.

Fundamental Health Fundamentally, VSTM faces substantial challenges, with minimal revenue generation and deeply negative profit margins due to high R&D spending. Although liquidity ratios appear adequate, negative cash flow from operations and a weak cash-to-debt ratio raise sustainability concerns. Operational efficiency is poor, as reflected by negative returns on assets and capital employed, indicating ineffective use of resources.

Valuation & Risk Assessment Valuation metrics are largely negative or distorted due to unprofitability and negative book value, making traditional analysis difficult. The elevated price-to-sales ratio lacks context without meaningful revenue growth. Risks include high volatility despite low beta, illiquidity concerns, and the possibility of unresolved operational or liquidity issues not fully captured by standard metrics.

Investment Recommendation

Based on the analysis, VSTM is not recommended for purchase at this time. The combination of persistent technical weakness, unsustainable financials, and negative operational metrics indicates high risk without clear catalysts for improvement. While the stock is not at its lows, the underlying business challenges and lack of profitability suggest limited near-term upside. Investors should monitor for signs of revenue growth or cost discipline before considering an entry.

CTA Banner

VSTM 12-Month Price Forecast

RockFlow Model Forecast: Three Scenarios for 2026

Based on the comprehensive analysis provided, the 12-month outlook for VSTM is highly cautious. Key catalysts for a potential turnaround are notably absent in the current profile; the company would need to demonstrate a significant breakthrough in its R&D pipeline leading to substantial revenue generation or announce a major strategic shift to improve its unsustainable financials. The primary risks are dominant and include persistent cash burn, the threat to its operational viability, and continued technical weakness driven by a lack of investor confidence. In the absence of analyst targets and given the fundamental challenges, the risk/reward profile is unfavorable, with the potential for further downside outweighing the likelihood of a material recovery.

Wall Street Consensus

Most Wall Street analysts are optimistic about VSTM's 12-month outlook, with consensus target around $7.11, indicating expected upside potential.

Average Target
$7.11
9 analysts
Implied Upside
+0%
vs. current price
Analyst Count
9
covering this stock
Price Range
$6 - $9
Analyst target range
Buy Buy
9 (100%)
Hold Hold
0 (0%)
Sell Sell
0 (0%)

Bulls vs Bears: VSTM Investment Factors

Overall, VSTM has investment potential but also faces challenges. Here are key factors to weigh before investing.

Bullish Bullish
  • Strong Q3 Financial Performance: Company beat Q3 revenue and earnings forecasts.
  • Positive Analyst Upgrade: Zacks upgraded the stock to a Buy rating on earnings optimism.
  • Promising Clinical Data: Updated Phase 1/2 data for VS-7375 showed promising results.
  • Technical Support Indication: Hammer chart pattern suggests the stock may have found a bottom.
Bearish Bearish
  • Significant Stock Price Decline: Stock fell 16-26% recently due to negative sentiment.
  • Rising Costs and Debt: Q3 beat was overshadowed by concerns over increasing financial burdens.
  • Negative Data from Partner: GenFleet's PDAC study showed lower efficacy, hurting investor confidence.
  • High Trading Volume on Downside: High sell-side volume indicates strong negative momentum.
Reward Banner

VSTM Technical Analysis

VSTM has demonstrated significant weakness with substantial declines across multiple timeframes and notable underperformance relative to the broader market.

The stock has experienced severe short-term pressure, declining 26.25% over one month and 12.18% over three months, substantially underperforming the market by 15.22 percentage points during the latter period despite its low beta suggesting defensive characteristics.

Currently trading at $7.64, VSTM sits approximately midway within its 52-week range of $4.01 to $11.245, indicating it has recovered from its lows but remains significantly below recent highs, suggesting neither extreme overbought nor oversold conditions despite the substantial maximum drawdown of -51.29%.

šŸ“Š Beta
0.44
0.44x market volatility
šŸ“‰ Max Drawdown
-51.3%
Largest decline past year
šŸ“ˆ 52-Week Range
$4-$11
Price range past year
šŸ’¹ Annual Return
+33.1%
Cumulative gain past year
Period VSTM Return S&P 500
1m -29.0% +1.1%
3m -20.5% +3.3%
6m +51.6% +12.0%
1y +33.1% +19.6%
ytd -1.7% +1.8%

VSTM Fundamental Analysis

Revenue & Profitability: VSTM shows minimal revenue generation with $11.2 million in Q3 2025, while reporting substantial net losses of $98.5 million. The company maintains a strong gross profit margin of 85%, but operating expenses, particularly R&D at $29 million, drive deeply negative operating and net profit margins of -362% and -876% respectively, indicating unsustainable operations.

Financial Health: The company maintains adequate liquidity with current and quick ratios near 2.5, though these are supported by negative cash flow from operations. The debt ratio of 0.51 shows manageable leverage, but the cash flow to debt ratio of -0.40 indicates insufficient operating cash flow to service obligations, raising concerns about long-term sustainability.

Operational Efficiency: Operational metrics show significant challenges, with negative return on assets (-56%) and return on capital employed (-35%), reflecting poor asset utilization. The asset turnover of 0.06 indicates inefficient use of assets to generate revenue, while the negative cash conversion cycle of -382 days suggests the company is delaying payments to suppliers to manage cash flow.

Quarterly Revenue
$0.0B
2025-09
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A%
Latest Quarter
Free Cash Flow
$-0.1B
Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

RockFlow Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

Try Now & Get Tesla Stock Reward

Valuation Analysis: Is VSTM Overvalued?

VSTM's valuation metrics present a concerning picture, as nearly all key ratios are negative, indicating the company is currently unprofitable and has negative book value. The negative PE, PB, and EV/EBITDA ratios reflect fundamental financial distress rather than meaningful valuation multiples. While the PS ratio of 38.73 appears extremely elevated, it must be viewed in the context of minimal revenue generation capacity given the company's financial condition.

Unfortunately, a meaningful peer comparison cannot be conducted due to the unavailability of industry average data. However, VSTM's negative profitability and book value metrics would likely place it as a significant outlier within any competitive landscape. The inability to benchmark against industry norms underscores the challenges in assessing relative valuation for a company exhibiting such fundamental financial difficulties.

Current PE
-1.7x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -10Ɨ--1Ɨ
vs. Industry Avg
N/A
Industry PE ~N/AƗ
EV/EBITDA
-6.1x
Enterprise Value Multiple

Investment Risk Disclosure

Volatility Risk: With a beta of 0.436, VSTM exhibits significantly lower volatility than the broader market. However, this low beta is overshadowed by a substantial maximum drawdown of -51.29% over the past year, indicating that despite its overall low correlation, the stock has experienced severe downside price movements. This presents a high volatility risk for investors focused on capital preservation.

Other Risks: The notable absence of reported short interest suggests a lack of significant speculative bets against the company, which can be interpreted as a minor positive in terms of sentiment. However, a stock lacking short interest can also be characteristic of an illiquid or neglected security, raising potential concerns about market depth and the ability to execute trades efficiently. The exceptionally large drawdown warrants careful consideration of underlying business or liquidity risks not fully captured by standard metrics.

FAQs

Is VSTM a good stock to buy?

Bearish. The stock faces severe technical weakness with substantial recent declines, shows unsustainable fundamentals due to deep losses and negative cash flow, and carries high volatility risk despite low beta. This speculative stock may only suit aggressive, high-risk investors betting on long-term pipeline success despite current financial distress.

Is VSTM stock overvalued or undervalued?

Based on the provided data, VSTM is significantly overvalued.

While comparison against industry peers is not possible, the company's valuation metrics are exceptionally poor. The PS ratio of 38.73 is extraordinarily high, and the negative PE, PB, and Forward PE ratios indicate a complete lack of profitability and negative shareholder equity.

This overvaluation exists despite the company's unsustainable financial state, characterized by massive net losses (-876% margin) and negative operational cash flow. The market price appears to be disconnected from the fundamental reality of a company burning cash with minimal revenue.

What are the main risks of holding VSTM?

Based on VSTM's profile, here are the key risks of holding the stock, ordered by importance:

1. Unsustainable Operations and Profitability: The company is burning substantial cash with deeply negative profit margins (-876% net margin) and negative cash flow from operations, indicating a high risk of financial distress without significant external funding. 2. Severe Price Volatility and Downside Risk: Despite a low market beta, the stock has experienced a severe maximum drawdown of -51.29% and recent sharp declines, signaling high volatility risk and potential for significant capital loss. 3. Poor Operational Efficiency and Utilization: Extremely low asset turnover (0.06) and deeply negative returns on assets (-56%) reflect fundamental inefficiency in using capital to generate revenue. 4. Potential Liquidity and Market Depth Concerns: The combination of negative cash flow, a lack of reported short interest, and substantial price declines raises concerns about the stock's market liquidity and the company's ability to manage its cash flow via delayed supplier payments.

What is the price forecast for VSTM in 2026?

Based on the provided analysis, here is a forecast for VSTM stock through 2026.

Our base case for 2026 is a price range of $3-$5, while a bull case would require a major positive catalyst to reach $8-$10.

Key growth drivers would be a successful commercial launch of a new drug from its pipeline, a strategic partnership that provides non-dilutive funding, or an acquisition of the company. The main assumptions are that the company can navigate its cash burn without severely diluting shareholders and that its R&D efforts yield tangible progress.

This forecast is highly uncertain and speculative, as VSTM's current unsustainable financials and lack of near-term catalysts present a significant risk of further downside or even operational failure, making the path to 2026 exceptionally challenging.